The incretins: a link between nutrients and well-being
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The glucoincretins, glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP), are intestinal peptides secreted in response to glucose or lipid intake. Data on isolated intestinal tissues, dietary treatments and knockout mice strongly suggest that GIP and GLP-1 secretion requires glucose and lipid metabolism by intestinal cells. However, incretin secretion can also be induced by non-digestible carbohydrates and involves the autonomic nervous system and endocrine factors such as GIP itself and cholecystokinin. The classical pharmacological approach and the recent use of knockout mice for the incretin receptors have shown that a remarkable feature of incretins is the ability to stimulate insulin secretion in the presence of hyperglycaemia only, hence avoiding any hypoglycaemic episode. This important role is the basis of ongoing clinical trials using GLP-1 analogues. Since most of the data concern GLP-1, we will focus on this incretin. In addition, GLP-1 is involved in glucose sensing by the autonomic nervous system of the hepato-portal vein controlling muscle glucose utilization and indirectly insulin secretion. GLP-1 has been shown to decrease glucagon secretion, food intake and gastric emptying, preventing excessive hyperglycaemia and overfeeding. Another remarkable feature of GLP-1 is its secretion by the brain. Recently, elegant data showed that cerebral GLP-1 is involved in cognition and memory. Experiments using knockout mice suggest that the lack of the GIP receptor prevents diet-induced obesity. Consequently, macronutrients controlling intestinal glucose and lipid metabolism would control incretin secretion and would consequently be beneficial for health. The control of incretin secretion represents a major goal for new therapeutic as well as nutrition strategies for treating and/or reducing the risk of hyperglycaemic syndromes, excessive body weight and thus improvement of well-being.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 2×
“The first study on the GLP-1 receptor knockout reported that the mice developed normally, but exhibited increased levels of blood glucose following oral glucose challenge (Scrocchi et al. 1996).”
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792 · cited 3×
“In the late 1960s it was further demonstrated that an oral glucose load induced a higher insulin secretion than intravenously administered glucose while blood glucose levels were similar between the two modes of delivery, suggesting that glucose clearance was different and involved different…”
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731
Herrmann, C., Göke, R., Richter, G., Fehmann, H.-C., Arnold, R., & Göke, B. (2009) · Digestion · doi:10.1159/000201231 · Cited by 597
Exon duplication and divergence in the human preproglucagon gene
Bell, G. I., Sanchez-Pescador, R., Laybourn, P. J., & Najarian, R. C. (1983) · Nature · doi:10.1038/304368a0 · Cited by 593
Research works printed but not linked: 120
- 10.1177/000456328902600214 · DOI
- Widmann, 1994, Signal transduction by the cloned glucagon-like peptide-1 receptor: comparison with signaling by the endogenous receptors of beta cell lines, Mol Pharmacol, 45, 1029
- 10.1172/JCI117671 · DOI · Paper page
- 10.1016/0014-5793(94)00553-2 · DOI · Paper page
- 10.1016/0143-4179(92)90036-V · DOI
- 10.2337/diab.43.6.752 · DOI
- 10.1016/0006-8993(83)91332-X · DOI · Paper page
- 10.1016/0167-0115(88)90037-7 · DOI
- Schmitt, 1973, Influence of hepatic portal receptors on hypothalamic feeding and satiety centers, Am J Physiol, 225, 1089, 10.1152/ajplegacy.1973.225.5.1089 · DOI · Paper page
- 10.1172/JCI118411 · DOI · Paper page
- 10.1074/jbc.270.44.26488 · DOI · Paper page
- 10.1073/pnas.91.8.3242 · DOI · Paper page
- 10.1053/meta.2000.6251 · DOI
- 10.1210/endo.137.6.8641190 · doi:10.1210/endo.137.6.8641190 · Paper page
- 10.1210/endo.137.9.8756571 · doi:10.1210/endo.137.9.8756571 · Paper page
- 10.1172/JCI118410 · DOI · Paper page
- 10.2337/diab.40.12.1659 · DOI · Paper page
- 10.1038/247284a0 · DOI · Paper page
- 10.1038/222282a0 · DOI · Paper page
- Oomura, 1981, Chemosensitive neuron in the hypothalamus related to food intake behavior, Jpn J Pharmacol, 31, 1P, 10.1016/S0021-5198(19)54826-0 · doi:10.1016/s0021-5198(19)54826-0
- 10.1093/ajcn/53.1.155 · DOI
- 10.1113/jphysiol.1985.sp015733 · DOI
- 10.1210/endo.138.10.5574 · doi:10.1210/endo.138.10.5574 · Paper page
- Nauck, 1993, Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7–36) amide infused at near-physiological insulinotropic hormone and glucose concentrations, J Clin Endocrinol Metab, 76, 912
- Nauck, 1996, Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes, Diabet Med, 13, S39
- Moore, 1996, Neural and pancreatic influences on net hepatic glucose uptake and glycogen synthesis, Am J Physiol, 271, E215
- 10.1016/S0899-9007(97)85073-4 · doi:10.1016/s0899-9007(97)85073-4
- 10.1016/0014-5793(84)81114-X · DOI · Paper page
- 10.1016/0006-8993(89)90628-8 · DOI
- 10.1016/S0140-6736(87)91194-9 · DOI · Paper page
- 10.2337/diab.38.7.902 · DOI · Paper page
- 10.2337/diab.44.1.16 · DOI · Paper page
- 10.1002/(SICI)1099-1263(199801/02)18:1<47::AID-JAT474>3.0.CO;2-S · doi:10.1002/(sici)1099-1263(199801/02)18:1<47::aid-jat474>3.0.co;2-s
- Jehle, 1995, Effects of glucagon-like peptide-1 (GLP-1) in RINm5F insulinoma cells. Stimulation of insulin secretion, insulin content, and insulin receptor binding, Exp Clin Endocrinol Diabetes, 2, 31
- 10.1016/0026-0495(93)90037-O · DOI
- 10.1038/361362a0 · DOI · Paper page
- 10.1016/0014-5793(87)81430-8 · DOI · Paper page
- 10.1016/0016-5085(94)90831-1 · DOI · Paper page
- 10.2337/diabetes.49.1.8 · DOI · Paper page
- 10.2337/diab.46.9.1521 · DOI · Paper page
- 10.1677/joe.0.1470025 · DOI · Paper page
- 10.1016/0026-0495(95)90021-7 · DOI
- 10.1152/ajpgi.2000.278.6.G924 · DOI · Paper page
- 10.1007/BF02576216 · DOI
- Goke, 1997, The intestinal hormone glucagon-like peptide 1 (GLP-1): from experiment to the clinic, Z Gastroenterol, 35, 285
- 10.1016/0014-5793(86)80697-4 · DOI · Paper page
- 10.1677/jme.0.0100259 · DOI · Paper page
- 10.1016/S0006-8993(97)00190-X · DOI
- 10.2337/diab.42.9.1253 · DOI · Paper page
- Fridolf, 1991, GLP-1(7–36) amide stimulates insulin secretion in rat islets: studies on the mode of action, Diabetes Res, 16, 185
- 10.1016/0167-4889(91)90200-H · DOI
- 10.1016/S0006-8993(97)01057-3 · DOI · Paper page
- 10.1007/s004419900093 · DOI
- 10.2337/diacare.19.6.580 · DOI · Paper page
- Creutzfeldt, 1992, Entero-insular axis and diabetes mellitus, Horm Metab Res, 26, 13
- 10.1210/endo.134.5.8156917 · doi:10.1210/endo.134.5.8156917 · Paper page
- 10.1002/(SICI)1096-9136(199610)13:10<854::AID-DIA262>3.0.CO;2-E · DOI
- 10.2337/diabetes.50.8.1720 · DOI · Paper page
- 10.2337/diabetes.49.10.1643 · DOI · Paper page
- 10.1111/j.1749-6632.1999.tb08510.x · DOI
- 10.2337/diabetes.50.6.1282 · DOI · Paper page
- 10.1007/BF00492251 · DOI · Paper page
- 10.1210/endo-123-4-2009 · DOI · Paper page
- 10.1210/endo-128-6-3175 · DOI · Paper page
- Brown, 1970, A multiparameter study on the action of preparations containing cholecystokinin pancreozymin, Scand J Gastroenterol, 5, 537, 10.1080/00365521.1970.12096632 · DOI · Paper page
- 10.1139/o71-037 · DOI · Paper page
- 10.1007/BF02914270 · DOI
- 10.2337/diab.38.1.7 · DOI · Paper page
- 10.1016/0165-1838(83)90039-5 · DOI
- Banting, 1922, The internal secretion of the pancreas, J Lab Clin Med, 7, 251
- Balkan, 2000, Portal GLP1 administration in rats augments the insulin response to glucose via neuronal mechanisms, Am J Physiol, 279, R1449
- Holst, 1996, GLP-1 in NIDDM, Diabet Med, 13, S156, 10.1002/dme.1996.13.s6.156 · doi:10.1002/dme.1996.13.s6.156
- 10.1046/j.1471-4159.1996.66030920.x · DOI · Paper page
- 10.1016/S0014-2999(00)00600-2 · DOI · Paper page
- Ahrén, 1997, Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus, J Clin Endocrinol Metab, 82, 473
- 10.1152/ajpregu.00423.2003 · DOI · Paper page
- 10.1016/S0026-0495(96)90066-9 · DOI
- 10.1007/BF00745145 · DOI
- 10.1007/BF00581038 · DOI
- 10.1007/s005920050059 · DOI
- 10.2337/diab.42.11.1678 · DOI · Paper page
- 10.2337/diab.42.9.1219 · DOI · Paper page
- 10.1210/endo-111-5-1601 · DOI · Paper page
- Ahrén, 1999, Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice, Am J Physiol, 277, E996
- 10.1016/S0014-5793(97)00254-8 · DOI
- Orskov, 1987, Pancreatic and intestinal processing of proglucagon in man, Diabetologia, 30, 874, 10.1007/BF00274797 · DOI · Paper page
- 10.1016/S0026-0495(96)90192-4 · DOI
- 10.1016/0014-5793(88)81063-9 · DOI · Paper page
- 10.1093/jn/128.7.1099 · DOI
- 10.1146/annurev.physiol.59.1.257 · DOI · Paper page
- 10.2337/diab.47.2.159 · DOI · Paper page
- 10.1007/s001250051347 · DOI
- Nakabayashi, 1996, Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1, Am J Physiol, 271, E808
- 10.1172/JCI112855 · DOI · Paper page
- 10.1016/0742-8413(95)00046-1 · DOI
- 10.1016/0167-0115(93)90137-W · DOI
- Balks, 1997, Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors, J Clin Endocrinol Metab, 82, 786
- 10.2337/diab.43.4.535 · DOI · Paper page
- 10.1113/jphysiol.1902.sp000920 · DOI · Paper page
- Goke, 1989, Signal transmission after GLP-1(7–36)amide binding in RINm5F cells, Am J Physiol, 257, G397
- 10.1530/eje.0.1350425 · DOI · Paper page
- 10.1210/endo.136.12.7588313 · doi:10.1210/endo.136.12.7588313 · Paper page
- 10.1016/0304-3940(84)90444-0 · DOI · Paper page
- 10.1210/endo-121-3-1076 · DOI · Paper page
- 10.1016/0168-8227(92)90024-L · DOI
- 10.1007/BF00417698 · DOI
- 10.1111/j.1749-6632.1969.tb12914.x · DOI · Paper page
- 10.1073/pnas.84.20.7005 · DOI · Paper page
- 10.1006/bbrc.2000.2288 · DOI
- Thiele, 1997, Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats, Am J Physiol, 272, R726
- 10.1097/00006676-199005000-00019 · DOI
- 10.1097/00006676-199007000-00018 · DOI · Paper page
- 10.2337/diab.44.9.1126 · DOI · Paper page
- 10.1111/j.1464-5491.1993.tb01995.x · DOI · Paper page
- 10.1210/endo.140.4.6643 · doi:10.1210/endo.140.4.6643 · Paper page
- 10.1054/npep.1999.0053 · DOI
- 10.3109/00365529609009147 · DOI · Paper page
- 10.1038/nm0903-1113 · DOI
- Nauck, 1996, Release of glucagon-like peptide 1 (GLP-1 [7–36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections, Z Gastroenterol, 34, 159
- 10.1677/joe.0.1450521 · DOI · Paper page
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“488 – 490 In the pancreas, this stimulates the secretion of insulin and inhibits the secretion of glucagon.”
BackgroundInulin-Type Fructans: Functional Food Ingredients
Roberfroid, M. B. (2007) · The Journal of Nutrition · doi:10.1093/jn/137.11.2493s · Cited by 878
The Brain, Appetite, and Obesity
Berthoud, H.-R., & Morrison, C. (2008) · Annual Review of Psychology · doi:10.1146/annurev.psych.59.103006.093551 · Cited by 641
Cani, P. D., Knauf, C., Iglesias, M. A., Drucker, D. J., Delzenne, N. M., & Burcelin, R. (2006) · Diabetes · doi:10.2337/db05-1360 · Cited by 405
Self-citationIntestinal microflora and metabolic diseases
Serino, M., Luche, E., Chabo, C., Amar, J., & Burcelin, R. (2009) · Diabetes & Metabolism · doi:10.1016/j.diabet.2009.03.003 · Cited by 77
Self-citation
Metadata
- Authors
- Burcelin, R.
- Venue
- British Journal of Nutrition
- Publisher
- Cambridge University Press (CUP)
- Published
- 2005-04
- Volume
- 93
- Issue
- S1
- Pages
- S147-S156
- ISSN
- 0007-1145 (ISSN-L)
- 1475-2662
- OpenAlex
- W1984290796
- Cited by
- 70
- References
- 28
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The incretins: a link between nutrients and well-being. https://app.cochat.ai/papers/10.1079/bjn20041340
- The paper
- Burcelin, R. (2005). The incretins: a link between nutrients and well-being. British Journal of Nutrition. https://doi.org/10.1079/bjn20041340
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.